92 related articles for article (PubMed ID: 14757498)
1. Integrated pharmacokinetic-pharmacodynamic modeling and allometric scaling for optimizing the dosage regimen of the monoclonal ior EGF/r3 antibody.
Duconge J; Castillo R; Crombet T; Alvarez D; Matheu J; Vecino G; Alonso K; Beausoleil I; Valenzuela C; Becquer MA; Fernández-Sánchez E
Eur J Pharm Sci; 2004 Feb; 21(2-3):261-70. PubMed ID: 14757498
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal anti-epidermal growth factor receptor (ior EGF/r3) antibody pharmacokinetic studies on nude mice I: a radio-receptor analysis applied to drug serum quantification.
Fernandez-Sánchez E; Ducongé J; Castillo R; Garcia I; Beausoleil I; Macías A
J Pharm Pharmacol; 2002 Jan; 54(1):59-64. PubMed ID: 11829130
[TBL] [Abstract][Full Text] [Related]
3. Interspecies scaling of the monoclonal anti-EGF receptor ior EGF/r3 antibody disposition using allometric paradigm: is it really suitable?
Ducongé J; Fernández-Sánchez E; Alvarez D
Biopharm Drug Dispos; 2004 May; 25(4):177-86. PubMed ID: 15108220
[TBL] [Abstract][Full Text] [Related]
4. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
[TBL] [Abstract][Full Text] [Related]
5. Death receptor 5 agonistic antibody PRO95780: preclinical pharmacokinetics and concentration-effect relationship support clinical dose and regimen selection.
Xiang H; Reyes AE; Eppler S; Kelley S; Damico-Beyer LA
Cancer Chemother Pharmacol; 2013 Aug; 72(2):405-15. PubMed ID: 23771513
[TBL] [Abstract][Full Text] [Related]
6. Onartuzumab (MetMAb): using nonclinical pharmacokinetic and concentration-effect data to support clinical development.
Xiang H; Bender BC; Reyes AE; Merchant M; Jumbe NL; Romero M; Davancaze T; Nijem I; Mai E; Young J; Peterson A; Damico-Beyer LA
Clin Cancer Res; 2013 Sep; 19(18):5068-78. PubMed ID: 23894056
[TBL] [Abstract][Full Text] [Related]
7. Preparation and comparative evaluation of 99mTc-labeled 2-iminothiolane modified antibodies and CITC-DTPA immunoconjugates of anti-EGF-receptor antibodies.
Mishra AK; Iznaga-Escobar N; Figueredo R; Jain VK; Dwarakanath BS; Pérez-Rodríguez R; Sharma RK; Mathew TL
Methods Find Exp Clin Pharmacol; 2002 Dec; 24(10):653-60. PubMed ID: 12616957
[TBL] [Abstract][Full Text] [Related]
8. Biodistribution of 99mTc-labeled anti-human epidermal growth factor receptor (EGF-R) humanized monoclonal antibody h-R3 in a xenograft model of human lung adenocarcinoma.
Morales-Morales A; Ducongé J; Caballero-Torres I; Núñez-Gandolff G; Fernández E; Iznaga-Escobar N
Nucl Med Biol; 1999 Apr; 26(3):275-9. PubMed ID: 10363798
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal anti-EGFreceptor antibody (ior-R3) pharmacokinetic study in tumor bearing nude mice: role of the receptor-mediated endocytosis on drug clearance.
Duconge J; Fernández-Sánchez E; Macías A; Castillo R; Garcia I; Beausoleil I; Amador JF; Matheu J
Eur J Drug Metab Pharmacokinet; 2002; 27(2):101-5. PubMed ID: 12064367
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies.
Baselga J; Norton L; Masui H; Pandiella A; Coplan K; Miller WH; Mendelsohn J
J Natl Cancer Inst; 1993 Aug; 85(16):1327-33. PubMed ID: 8340945
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of monoclonal anti-epidermal growth factor receptor antibody (IOR EGF/r3)-induced apoptosis in human carcinoma bearing nude mice.
Ducongé J; Merino N; Alvarez D; Beausoleil I; Fernández-Sánchez E; Rodríguez L; Burt AD
P R Health Sci J; 2008 Mar; 27(1):35-41. PubMed ID: 18450231
[TBL] [Abstract][Full Text] [Related]
12. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy.
Bleeker WK; Lammerts van Bueren JJ; van Ojik HH; Gerritsen AF; Pluyter M; Houtkamp M; Halk E; Goldstein J; Schuurman J; van Dijk MA; van de Winkel JG; Parren PW
J Immunol; 2004 Oct; 173(7):4699-707. PubMed ID: 15383606
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans.
Mordenti J; Thomsen K; Licko V; Chen H; Meng YG; Ferrara N
Toxicol Pathol; 1999; 27(1):14-21. PubMed ID: 10367667
[TBL] [Abstract][Full Text] [Related]
14. Technetium-99m-antiepidermal growth factor-receptor antibody in patients with tumors of epithelial origin: part II. Pharmacokinetics and clearances.
Iznaga-Escobar N; Torres Arocha LA; Morales Morales A; Ramos Suzarte M; Rodríguez Mesa N; Pérez Rodríguez R
J Nucl Med; 1998 Nov; 39(11):1918-27. PubMed ID: 9829584
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor.
Crombet T; Torres O; Neninger E; Catalá M; Rodríguez N; Ramos M; Fernández E; Iznaga N; Pérez R; Lage A
Cancer Biother Radiopharm; 2001 Feb; 16(1):93-102. PubMed ID: 11279803
[TBL] [Abstract][Full Text] [Related]
16. The anti-EGFR monoclonal antibody blocks cisplatin-induced activation of EGFR signaling mediated by HB-EGF.
Yoshida T; Okamoto I; Iwasa T; Fukuoka M; Nakagawa K
FEBS Lett; 2008 Dec; 582(30):4125-30. PubMed ID: 19027738
[TBL] [Abstract][Full Text] [Related]
17. Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer.
Feng L; Yao HP; Zhou YQ; Zhou J; Zhang R; Wang MH
J Exp Clin Cancer Res; 2016 Apr; 35():70. PubMed ID: 27102688
[TBL] [Abstract][Full Text] [Related]
18. Tumor targeting using anti-epidermal growth factor receptor (ior egf/r3) immunoconjugate with a tetraaza macrocyclic agent (DO3A-EA).
Mishra G; Panwar P; Mishra AK
Mol Imaging; 2012; 11(5):408-16. PubMed ID: 22954185
[TBL] [Abstract][Full Text] [Related]
19. Predicting Antitumor Effect of Deoxypodophyllotoxin in NCI-H460 Tumor-Bearing Mice on the Basis of In Vitro Pharmacodynamics and a Physiologically Based Pharmacokinetic-Pharmacodynamic Model.
Chen Y; Zhao K; Liu F; Li Y; Zhong Z; Hong S; Liu X; Liu L
Drug Metab Dispos; 2018 Jun; 46(6):897-907. PubMed ID: 29618575
[TBL] [Abstract][Full Text] [Related]
20. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
